Related Experiment Video

Updated: Jul 1, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Dacarbazine Resistance in Melanoma Is Driven by Cell Cycle Dysregulation Stemming from Altered Cyclin D1, GSK-3β, and

Chinami Ikushima1, Kazuki Nakamura1, Kazuyuki Furuta2

  • 1Department of Pharmacology I, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan.

Anticancer Research
|June 29, 2026
PubMed
Abstract

Insights

Programmed cell death 4 (Pdcd4) downregulation in melanoma cells contributes to dacarbazine (DTIC) resistance by disrupting cell cycle control. Restoring Pdcd4 may overcome this chemotherapy resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Advanced metastatic melanoma has poor response rates and prognosis.
  • Dacarbazine (DTIC) resistance is a major challenge in melanoma treatment.
  • Programmed cell death 4 (Pdcd4) is a tumor suppressor gene with unclear roles in cell cycle regulation and drug resistance.

Purpose of the Study:

  • Investigate the role of Pdcd4 in dacarbazine (DTIC) resistance in melanoma.
  • Elucidate the mechanisms by which Pdcd4 influences cell cycle regulation in DTIC-resistant melanoma cells.

Main Methods:

  • Established DTIC-resistant mouse melanoma cell lines.
  • Utilized western blotting and flow cytometry to analyze cell cycle regulatory factors.
  • Examined the correlation between Pdcd4 expression and cell cycle progression.

Main Results:

  • DTIC-resistant cells exhibited significantly decreased Pdcd4 protein levels.
  • Upregulation of Cyclin D1, Cyclin E, and p21 was observed in resistant cells.
  • DTIC treatment failed to reduce the S-phase population in resistant cells, unlike in sensitive cells.

Conclusions:

  • Downregulation of Pdcd4 is associated with DTIC resistance in melanoma.
  • Disrupted cell cycle control, linked to low Pdcd4, contributes to chemotherapy resistance.
  • Reactivating Pdcd4 presents a potential strategy to overcome dacarbazine resistance in melanoma patients.
Keywords:
Dacarbazinecell cycle dysregulationmelanomaresistant

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.